Skip to content

Cancers & treatments

News & evidence

Living with cancer

Learn & contribute

Loading

A public, cited, editable map of oncology: technologies, targets, products, companies, institutions, pathways, trials, pairings, roadmaps, and ideas. One page per object, with a plain-language TL;DR on every page.

Work in progress. Every fact on this site is being built and checked in the open and may be incomplete, out of date, or wrong. You must do your own research and verify anything here at its primary source before relying on it. Nothing on this site is medical advice; decisions belong with you and your clinicians.

OnCo is an information resource, not medical advice. Nothing here replaces a conversation with a qualified clinician. Never delay care because of something you read here; in an emergency, call your local emergency services. Terms of use

Browse by cancer
Tags
Search
Connections
For me
Navigator
Biomarker matrix
Calculators
Interactions
Decision aids
Checkpoint side effects
Tumour board
Compare
Counts by category
Rankings
Timeline
Year by year
Query builder
Graph explorer
Saved
Body map

Cancers & treatments

News & evidence

Institutions & people

Institutions
Universities
Trial leadership
People
Heroes and heroines
Companies
Startups
Requests for startups
Investors
Company scorecards
Trial sponsors
Manufacturing map
Countries
United States deep dive
India deep dive
China deep dive
Germany deep dive
Israel deep dive
United Kingdom deep dive
Cases by country
Funding flows

Living with cancer

For me
The first 60 days
Appointment prep pack
Side effects
Symptom to test
Report reader
Survivorship planner
Second opinion
Financial help
Free in oncology
Paying for care in the US
NHS coverage
Paying for care in India
Coverage rankings
Cutting cancer care costs
Diet, exercise and lifestyle
Supportive care
Recovery and rejuvenation
Complementary and supportive approaches
Hair loss and regrowth
What comes back after treatment
Heroes and heroines

Learn & contribute

Reading paths
About & methodology
Roadmap
Gaps to fill
Coverage of the field
Review queue
Reviewer roster
Contributors
Idea votes
Teaching packs
Weekly issue
Suggest an edit
Answer quality
Data dictionary
Build on OnCo
Open API
Open data
Open tools
Open source in oncology
The software of oncology
GitHub

© 2026 OnCo. Code MIT. The data are free for individual and educational use with the attribution “Data from OnCo (onco.cc)”, under CC BY-NC 4.0. Commercial use must contact us to pay for the data. Commercial licences. Made with heart and soul by Jude Gomila .

About and methodology Corrections Open API Tags Terms of use Privacy policy GitHub

Loading

Home
Trials
Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma

trialsTrialCompleted

Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma

A phase 2 trial of Resminostat in Hodgkin lymphoma, run by 4SC AG, completed.

Overview Connected4

Overview

Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT01037478 by 4SC AG, with 37 participants recorded, started 2009-12 and reaching its primary completion in 2012-01. Interventions recorded: Resminostat (4SC-201). Conditions recorded: Hodgkin's Lymphoma.

Linked to the drug Resminostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.

Setting

A Phase 2 Proof of Concept Study to Evaluate the Efficacy, Safety and Pharmacokinetics of the HDAC Inhibitor 4SC-201 in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Phase

Phase 2

Sponsor

4SC AG

Registry

Started

2009-12

Enrolled

37 enrolled

Connected

Similar pages

Trial
4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma
Shares 4SC, Resminostat and the tag pipeline.
Trial
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)
Shares 4SC, Resminostat and the tag pipeline.
Trial
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma and the tag pipeline.
Trial
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Shares Hodgkin lymphoma and the tag pipeline.
Trial
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Shares Hodgkin lymphoma and the tag pipeline.
Treatment
Englumafusp alfa
Shares Hodgkin lymphoma and the tag pipeline.
Trial
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Hodgkin lymphoma and the tag pipeline.
Treatment
CD19 t-haNK
Shares Hodgkin lymphoma and the tag pipeline.

cancers

Hodgkin lymphoma Relapsed and refractory classical Hodgkin lymphoma

drugs

Small-molecule HDAC inhibitor

Resminostat · Kinselby

companies

Evidence strength23/100 · Preliminary

How much and what kind of evidence, not how big the benefit. Click for the breakdown.

Phase 2+15
37 enrolled+8
No structured primary endpoint0
Result: completed0
No independent replication recorded0

Formula disclosed on the evidence page.

ProvenanceLast edited 2026-09-22 · Jude Gomila · Wave 5 drugs · diff · file

Sources & links

ClinicalTrials.gov NCT01037478

Data

JSON ·

Follow this page

Wrong or missing?

Propose a change with a source. Organisations can update their own records. Every suggestion is reviewed, safety-checked and validated before it goes live; nothing is edited directly.

Suggest an editDiscuss start a thread

Out of date?
Report a readout
How review works

Cancers

Hodgkin lymphoma
Relapsed and refractory classical Hodgkin lymphoma

Products

Resminostat

Companies

4SC

Not yet reviewedNeeds expert (clinical) review. Review this page or see the review queue and roster.

Model panel commentary is coming to this page: machine commentary, not clinical review.

Machine-readable versions of Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma

JSON record with neighbours
Markdown context for language models
RDF Turtle for this record (its triples, relations and owl:sameAs; the IRI of this record is https://onco.cc/trials/nct01037478/)
All trials as JSON
RDF N-Triples for the whole corpus
Search index: id, kind, name, TL;DR and route for every record
OpenAPI 3.1 description
API root and meta.json
llms.txt

MCP server: npx -y onco-mcp, tools search, get_entity, list_kind, ask, context, compare. This record is get_entity or context with id nct01037478.

WebMCP tools registered on this page: onco_search, onco_get_entity.